In the Spring of 2018, Singapore issued a call for Public Comments on the topic of whether it should repeal the country’s current prohibition against germline modification of embryos and permit an exception for Mitochondrial Replacement Therapy. See the story here and here. ...
Tag: Risk
As Genetic Testing for Breast Cancer Gene Mutation Expands, Questions Arise About Treatment Decisions
posted by: Katherine Drabiak, J.D.
May 18, 2018
This post originally appeared on The Conversation on May 3, 2018. The Food and Drug Administration recently announced its authorization that permits genetics testing company 23andMe to market a test for gene mutations associated with risk of breast and ovarian cancer. In response, 23andMe CEO Anne Wojcicki asserted that...
Engineering Consensus in the Development of Genome Editing Policy
posted by: Katherine Drabiak, J.D.
March 14, 2017
This commentary was originally published as an Essay on the Hastings Center Bioethics Forum here. In the past few weeks media outlets have been reporting on the release of Human Genome Editing: Science, Ethics, and Governance from the National Academies of Science, Engineering, and...
Questions about Deaths in Cancer Trials using Gene-Altered Cells
posted by: Katherine Drabiak, J.D.
January 9, 2017
This article was originally posted on The Center for Genetics and Society’s site here. In the past month, the media has reported seven patient deaths of subjects enrolled in separate gene therapy clinical trials being conducted by Juno Therapeutics and by Ziopharm Oncology, Inc., both...
The Problem of Transparency and Human Genome Editing
posted by: Katherine Drabiak, J.D.
June 4, 2016
In the past several weeks, human genetic modification has been dominating headlines. This time, the controversy surrounded the closed door meeting between 130 scientists, attorneys, entrepreneurs, and government officials to discuss the creation of a synthetic human genome. The project, called “Human Genome Project-Write...